3.90

5.68% -0.235

After Hours: 3.90

Xenetic Biosciences Inc (XBIO)

Overview News Price History Financials Discussions Forecast Stock Split

Xenetic Biosciences Inc stock is currently priced at $3.90, with a 24-hour trading volume of 1,049. It has seen a -5.68% decreased in the last 24 hours and a -11.16% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.10 pivot point. If it approaches the $3.86 support level, significant changes may occur.

Previous Close:

$4.135

Open:

$3.95

24h Volume:

1,049

Market Cap:

$6.01M

Revenue:

$2.54M

Net Income/Loss:

$-4.13M

P/E Ratio:

-1.3495

EPS:

-2.89

Net Cash Flow:

$-4.11M

1W Performance:

+3.29%

1M Performance:

-11.16%

6M Performance:

+13.21%

1Y Performance:

-3.23%

1D Range:

$3.90

$4.02

52W Range:

$2.55

$5.97

Xenetic Biosciences Inc Stock (XBIO) Company Profile

Name

Xenetic Biosciences Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

781 778 7720

Address

40 Speen Street, Suite 102, Framingham, MA

Employee

Twitter

@XeneticBio

Next Earnings Date

2024-05-09

Latest SEC Filings

XBIO's Discussions on Twitter

Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-20	Initiated	Maxim Group	Buy

Xenetic Biosciences Inc Stock (XBIO) Financials Data

Xenetic Biosciences Inc (XBIO) Revenue 2024

XBIO reported a revenue (TTM) of $2.54 million for the quarter ending December 31, 2023, a +48.81% rise year-over-year.

Xenetic Biosciences Inc (XBIO) Net Income 2024

XBIO net income (TTM) was -$4.13 million for the quarter ending December 31, 2023, a +36.90% increase year-over-year.

Xenetic Biosciences Inc (XBIO) Cash Flow 2024

XBIO recorded a free cash flow (TTM) of -$4.11 million for the quarter ending December 31, 2023, a +20.06% increase year-over-year.

Xenetic Biosciences Inc (XBIO) Earnings per Share 2024

XBIO earnings per share (TTM) was -$2.75 for the quarter ending December 31, 2023, a +40.60% growth year-over-year.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.